3328 A randomized controlled phase II clinical trial on autologous monocyte-derived mRNA electroporated dendritic cells for stage III/IV melanoma patients who are disease-free following the local treatment of macrometastases

2015 ◽  
Vol 51 ◽  
pp. S673 ◽  
Author(s):  
Y. Jansen ◽  
J. Corthals ◽  
S. Wilgenhof ◽  
M. Schreuer ◽  
C. Heirman ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dendritic Cells ◽  
Phase Ii ◽  
Local Treatment ◽  
Phase Ii Clinical Trial ◽  
Stage Iii ◽  
Randomized Controlled ◽  
Melanoma Patients ◽  
Disease Free ◽  
Autologous Monocyte

scholarly journals Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

2012 ◽  
Vol 28 (4) ◽  
pp. 1131-1138 ◽  
Author(s):  
CHIE OSHITA ◽  
MASAKO TAKIKAWA ◽  
AKIKO KUME ◽  
HARUO MIYATA ◽  
TADASHI ASHIZAWA ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dendritic Cell ◽  
Metastatic Melanoma ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Melanoma Patients

A518 Dendritic Cells Immunotherapy: A Phase II Clinical Trial

2009 ◽  
Vol 9 ◽  
pp. S80-S81
Author(s):  
L Zahradova ◽  
A Stejskalova ◽  
H Novotna ◽  
I Jelinkova ◽  
M Penka ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dendritic Cells ◽  
Phase Ii ◽  
Phase Ii Clinical Trial

Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial

2020 ◽  
Author(s):  
Firas S. Ahmed ◽  
Laurent Dercle ◽  
Gregory V. Goldmacher ◽  
Hao Yang ◽  
Dana Connors ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase Ii ◽  
Advanced Melanoma ◽  
Phase Ii Clinical Trial ◽  
Recist 1.1 ◽  
Melanoma Patients
Sign in / Sign up

Export Citation Format

Share Document